WO2024218708 - BIOMARKER-BASED TREATMENT AND DIAGNOSTIC METHODS FOR IL-17-DEPENDENT CONDITIONS
National phase entry is expected:
Publication Number
WO/2024/218708
Publication Date
24.10.2024
International Application No.
PCT/IB2024/053796
International Filing Date
18.04.2024
Title **
[English]
BIOMARKER-BASED TREATMENT AND DIAGNOSTIC METHODS FOR IL-17-DEPENDENT CONDITIONS
[French]
MÉTHODES DE TRAITEMENT ET DE DIAGNOSTIC BASÉES SUR DES BIOMARQUEURS POUR DES AFFECTIONS DÉPENDANTES DE L'IL-17
Applicants **
MOONLAKE IMMUNOTHERAPEUTICS AG
Dorfstrasse 29
6300 Zug, CH
Inventors
REICH, Kristian
c/o MoonLake Immunotherapeutics AG
Dorfstrasse 29
6300 Zug, CH
CULLEN, Eva
c/o MoonLake Immunotherapeutics AG
Dorfstrasse 29
6300 Zug, CH
SOUTO PEREIRA, Sara Raquel
c/o MoonLake Immunotherapeutics AG
Rua Manuel Pinto de Azevedo, nº860 5º andar
frações I e J
4100-320 Porto, PT
GODWOOD, Alex
c/o MoonLake Immunotherapeutics AG
Regent Street 1st floor 95
Cambridge Cambridgeshire CB2 1AW, GB
SANTOS DA SILVA, Jorge
c/o MoonLake Immunotherapeutics AG
Dorfstrasse 29
6300 Zug, CH
Priority Data
63/460,230
18.04.2023
US
63/460,240
18.04.2023
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 3153 | |
| EPO | Filing, Examination | 30458 | |
| Japan | Filing | 530 | |
| South Korea | Filing | 607 | |
| USA | Filing, Examination | 18685 |
Total: 53433 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
Biomarker-based treatment, monitoring, and diagnostic methods for IL-17 dependent conditions, including hidradenitis suppurativa, are disclosed. The biomarkers may be selected from IL6, PLA2G2A, IL19, PI3, CST7, IL17A, IL17F, GH1, MZB1, IL1B, IFNG, TNC, CXCL9, SLAMF7, VEGFA, IL17C, SLAMF1, SDC1, OSM, LBP, REG3A, CD79B, COL4A1, CLEC4D, VWF, IL5RA, CSF3, TGFA, IL2RA, ITIH3, FCAR, CCL23, NRCAM, RETN, SERPINA11, CLEC4G, CSF1, HGF, CRELD2, EFEMP1, LTBR, NME3, CKAP4, CD276, SPON2, GGH, TIMP1, LY9, MCFD2, TCN2, QPCT, HYOU1, TNSFSF13B, CCL2, CCL3, CCL4, CCL5, CCL7, CCL20, CXCL1, CXCL8, PDFGA, CXCR2, CCR6, CXCL13, PCDH1, BOC, MEPE, ADAM23, THOP1, IL1RL2, RCOR1, EDAR, and combinations thereof. Kits for measuring the biomarkers, diagnosing and treating IL-17-dependent conditions, and identifying super-responders are also disclosed.[French]
Des méthodes de traitement, de surveillance et de diagnostic basées sur des biomarqueurs pour des affections dépendantes de l'IL-17, notamment l'hidradénite suppurée, sont divulguées. Les biomarqueurs peuvent être choisis parmi IL6, PLA2G2A, IL19, PI3, CST7, IL17A, IL17F, GH1, MZB1, IL1B, IFNG, TNC, CXCL9, SLAMF7, VEGFA, IL17C, SLAMF1, SDC1, OSM, LBP, REG3A, CD79B, COL4A1, CLEC4D, VWF, IL5RA, CSF3, TGFA, IL2RA, ITIH3, FCAR, CCL23, NRCAM, RETN, SERPINA11, CLEC4G, CSF1, HGF, CRELD2, EFEMP1, LTBR, NME3, CKAP4, CD276, SPON2, GGH, TIMP1, LY9, MCFD2, TCN2, QPCT, HYOU1, TNSFSF13B, CCL2, CCL3, CCL4, CCL5, CCL7, CCL20, CXCL1, CXCL8, PDFGA, CXCR2, CCR6, CXCL13, PCDH1, BOC, MEPE, ADAM23, THOP1, IL1RL2, RCOR1, EDAR et des combinaisons de ceux-ci. Des kits de mesure des biomarqueurs, de diagnostic et de traitement d'affections dépendantes de l'IL-17, et d'identification de super-répondeurs sont également divulgués.